Dr. Mark Wolters

Mark Wolters is an independent Member of the SequantrixTM Board. He has more than 25 years of pharmaceutical industry experience. Previously he was Vice President of Business Development & Licensing and Head of Early Licensing, and Vice President of the Bayer Life Science Center at Bayer, where he led a team of early-stage licensing and transaction professionals across an innovation ecosystem including biotech startups, academia, and the life sciences venture capital community. Mark has negotiated and closed hundreds of transaction of different types at Bayer and in his previous role as the Executive Director and Head of the Office of Technology at Schering AG, including the development of Bayer's joint ventures Casebia Therapeutics (with CRISPR Therapeutics), BlueRock Therapeutics (with Versant Ventures), and Joyn Bio (with Gingko Bioworks). He also serves on the Advisory Board of the Fraunhofer Institute for Cell Therapy and Immunology IZI in Leipzig, Germany. Mark received his Ph.D. in Molecular Biology from the Freie Universität Berlin and did his post-doctoral training in structural biology in the laboratory of Professor Alexander Rich at the Massachusetts Institute of Technology.